CRISPR Therapeutics and Vertex Pharmaceuticals (NASDAQ:VRTX) are awaiting a review from the U.S. Food and Drug Administration (FDA) for their joint product, exagamglogene autotemcel, it was announced on Wednesday. The two biotech giants have been leveraging the CRISPR/Cas9 technology to develop gene therapies aimed at several medical fields.
The collaborative efforts between CRISPR Therapeutics and Vertex target a wide range of ailments including diabetes, hemoglobinopathies, oncology-related diseases, regenerative medicine, and rare diseases. The companies' use of the CRISPR/Cas9 system has been central to these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.